Target Hemoglobin in Patients with Sickle Cell Disease
Hemoglobin Targets
- The American Society of Hematology recommends that hemoglobin levels should be maintained below 10 g/dL for most patients with SCD to prevent hyperviscosity and associated complications 1, 2
- For patients requiring preoperative transfusion, the target hemoglobin should be around 10 g/dL to avoid hyperviscosity 3, 4
- Hemoglobin should not be increased by more than 4 g/dL in a single transfusion episode to prevent complications 3, 5
Transfusion Strategies
- Simple transfusion is appropriate for patients with hemoglobin levels <9 g/dL, with post-transfusion targets not exceeding 11 g/dL 6
- Exchange transfusion should be considered for patients with hemoglobin levels >9-10 g/dL, targeting post-transfusion levels of 10-11 g/dL 6
- For high-risk surgeries, exchange transfusion with target HbS% <30% is recommended 3, 6
Special Considerations
- Patients with HbSC genotype may have naturally higher baseline hemoglobin; partial exchange transfusion may be needed to lower HbS% while allowing slightly higher hemoglobin 3, 7
- For patients on chronic transfusion programs, HbS% should be optimized to <30% preoperatively 3
Hemoglobin Targets in Specific Clinical Scenarios
- For SCD patients with worsening anemia due to chronic kidney disease, combination therapy with hydroxyurea and erythropoiesis-stimulating agents is suggested, with hemoglobin not exceeding 10 g/dL 1, 2
Potential Complications of Elevated Hemoglobin
- Exceeding the recommended hemoglobin threshold of 10 g/dL increases risk of vaso-occlusive complications, stroke, venous thromboembolism, and hyperviscosity syndrome 1, 2, 3, 4